List of Excipients in API travoprost ophthalmic solution, 0.004%
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing travoprost ophthalmic solution, 0.004%
Detailed excipient profiles for travoprost ophthalmic solution, 0.004%
Excipient focus: BORIC ACID
travoprost ophthalmic solution, 0.004% drug variants containing BORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing BORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
travoprost ophthalmic solution, 0.004% drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYOXYL 40 HYDROGENATED CASTOR OIL
travoprost ophthalmic solution, 0.004% drug variants containing POLYOXYL 40 HYDROGENATED CASTOR OIL
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing POLYOXYL 40 HYDROGENATED CASTOR OIL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
travoprost ophthalmic solution, 0.004% drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
travoprost ophthalmic solution, 0.004% drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
travoprost ophthalmic solution, 0.004% drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
travoprost ophthalmic solution, 0.004% drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ZINC CHLORIDE
travoprost ophthalmic solution, 0.004% drug variants containing ZINC CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | travoprost ophthalmic solution, 0.004% | 0378-9651 |
| >Company | >Ingredient | >NDC |
travoprost ophthalmic solution, 0.004% drug variants not containing ZINC CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch